journal article·2017-07-12

Microfluidic Mapping of Cancer Cell–Protein Binding Interaction

Zongbin Liu, Xin Han, Rui Chen, Kai Zhang, Ying Li, Shelby Fruge, Joon hee Jang, Yuan Ma, Lidong Qin

Publisher page

Abstract

The interaction between tumor cells and microenvironment during metastasis is mediated by the binding of cell surface receptors, such as integrins and selectins, with protein ligands. Delineation of their binding interaction and identification of key receptors may be particularly important both in understanding extracellular matrix (ECM) remodeling and in developing potential therapeutic targets. Here we present a microfluidic chip that allows qualitative and quantitative mapping of a large population cell-protein interactions. It was found that β1 integrin showed stronger binding interaction with collagen than with other ECM proteins. The upregulated β1 integrin in invasive cancer cells enhanced cell-ECM interaction and may promote ECM remodeling. Cancer cells also showed strong interaction with plasma fibrinogen, the elevated level of which may help cancer cells arrest on blood vessels. We also verified that the chip may provide a platform for drug discovery by targeting integrins and cytoskeletons.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cellular Mechanics and Interactions · Cell Adhesion Molecules Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States

Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, New York 10065, United States

The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510150, China

Division of Infectious Diseases, Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia 30302, United States

Funding

National Cancer Institute

References (35)

Show source-provided references
1. 10.1038/nrc308010.1038/nrc3080 ↗
2. 10.1016/j.yexcr.2013.02.00610.1016/j.yexcr.2013.02.006 ↗
3. 10.1083/jcb.20110214710.1083/jcb.201102147 ↗
4. 10.1038/nm.339410.1038/nm.3394 ↗
5. 10.1038/nrm390410.1038/nrm3904 ↗
6. 10.1007/s13277-013-1511-710.1007/s13277-013-1511-7 ↗
7. 10.1111/j.1349-7006.2009.01115.x10.1111/j.1349-7006.2009.01115.x ↗
8. 10.1182/blood-2004-02-043410.1182/blood-2004-02-0434 ↗
9. 10.1038/nrc300410.1038/nrc3004 ↗
10. 10.1038/bjc.2013.44310.1038/bjc.2013.443 ↗
11. 10.1038/nrc274810.1038/nrc2748 ↗
12. 10.1016/j.ceb.2013.06.01010.1016/j.ceb.2013.06.010 ↗
13. 10.1038/ncomms212810.1038/ncomms2128 ↗
14. 10.1016/j.biomaterials.2013.09.01410.1016/j.biomaterials.2013.09.014 ↗
15. 10.1073/pnas.060596010310.1073/pnas.0605960103 ↗
16. 10.1021/ac049837t10.1021/ac049837t ↗
17. 10.1242/jcs.03099910.1242/jcs.030999 ↗
18. 10.1038/nmeth.121810.1038/nmeth.1218 ↗
19. 10.1038/srep1427210.1038/srep14272 ↗
20. 10.1002/adhm.20160000910.1002/adhm.201600009 ↗
21. 10.1063/1.477430810.1063/1.4774308 ↗
22. 10.1158/1078-0432.CCR-03-082510.1158/1078-0432.CCR-03-0825 ↗
23. 10.1186/1471-2407-13-15410.1186/1471-2407-13-154 ↗
24. 10.2353/ajpath.2006.05132110.2353/ajpath.2006.051321 ↗
25. 10.1002/ijc.2167710.1002/ijc.21677 ↗
26. 10.1158/0008-5472.CAN-03-342410.1158/0008-5472.CAN-03-3424 ↗
27. 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.0.CO;2-P10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.0.CO;2-P ↗
28. 10.1016/j.ceb.2006.12.01310.1016/j.ceb.2006.12.013 ↗
29. 10.1016/S0955-0674(03)00109-110.1016/S0955-0674(03)00109-1 ↗
30. 10.1042/BST036023510.1042/BST0360235 ↗
31. 10.1158/0008-5472.CAN-05-307110.1158/0008-5472.CAN-05-3071 ↗
32. 10.1158/0008-5472.CAN-07-639010.1158/0008-5472.CAN-07-6390 ↗
33. 10.1186/1746-1596-7-10410.1186/1746-1596-7-104 ↗
34. 10.1186/bcr290510.1186/bcr2905 ↗
35. 10.1016/S0925-4773(97)00194-910.1016/S0925-4773(97)00194-9 ↗